Plasma-derived product · Immune activation, directed at SARS-CoV-2 spike protein · developed by Emergent BioSolutions
COVID-HIGIV is a purified immunoglobulin G preparation containing neutralizing antibodies to SARS-CoV-2, administered intravenously for COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04661839 | Phase 1 | COVID-19 | Completed | EBS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19
Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.
See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EBS catalysts and pipeline →